Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Lee's Pharmaceutical Holdings Ltd

LPCUF:PKC

Lee's Pharmaceutical Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1882
  • Today's Change0.00 / 0.00%
  • Shares traded320.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 15:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.

  • Revenue in HKD (TTM)1.20bn
  • Net income in HKD63.06m
  • Incorporated2001
  • Employees993.00
  • Location
    Lee's Pharmaceutical Holdings LtdUnit 110-111, Bio-Inf. Centre,No.2 Science Park West Avenue,Hong Kong Science Park, Shatin Hong KongHKG
  • Phone+852 23141282
  • Fax+852 23141708
  • Websitehttps://www.leespharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.